Source announced November 16, 2026: Cognito Therapeutics' topline HOPE trial results at the Clinical Trials on Alzheimer's Disease conference, checked against NCT05637801, the company's detailed results page and MIT's institutional account.
The overall result comes first HOPE was a 12-month, multicenter, randomized, double-blind, sham-controlled pivotal trial of an investigational at-home system that delivers synchronized 40 hertz light and sound for one hour daily. The study enrolled 673 people with biomarker-confirmed mild-to-moderate Alzheimer's disease. The company reports 663 participants in its modified intention-to-treat analysis population.
The trial did not meet its primary endpoint in the overall mild-to-moderate population. Change on iADMARS, a composite of cognition and daily function, did not differ significantly between active and sham treatment at month 12. The company also reported no statistically significant overall secondary endpoints.
A prespecified mild-disease signal The company had prespecified mild and moderate subgroups based on baseline Mini-Mental State Examination scores. Among 395 participants in the mild subgroup, results favored active treatment on three measures: 56% less decline on ADCS-ADL, nominal p=.016; 53% less decline on ADCS-iADL, nominal p=.034; and 47% less decline on CDR-SB, nominal p=.004.
Two other mild-subgroup measures did not reach statistical significance: iADMARS, nominal p=.072, and MMSE, nominal p=.369. The company states that the p-values were nominal and not adjusted for multiple comparisons. The moderate subgroup did not show clinical benefit. These differences make the mild-disease signal important to investigate, but they do not reverse the failed overall primary endpoint or by themselves establish efficacy.
Why adherence analyses need restraint A per-protocol analysis of 169 mild-disease participants who met treatment-use criteria produced larger favorable estimates. That can be informative about feasibility and exposure, but it is a more selected group. People who adhere closely may differ in ways that also affect outcomes. The full participant flow, missing-data handling, subgroup interaction tests and all prespecified analyses need peer-reviewed review before drawing clinical conclusions.
What the sponsor reported about safety Cognito reported adverse device effects in 18.3% of active participants and 15.5% of sham participants, with no observed unanticipated adverse device effects. Active-versus-sham event rates included headache, 5.7% versus 3.9%; tinnitus, 3.3% versus 1.2%; fatigue, 1.5% versus 0.3%; dizziness, 1.2% versus 1.8%; hallucination, 1.5% versus 0.9%; seizure, 0.9% versus 0.3%; and ear pain, 1.2% versus 0.3%. These are sponsor-reported topline results, not an independent adjudication or complete peer-reviewed safety analysis.
What is known, and what is not The randomized sham-controlled design, large enrollment and 12-month follow-up make HOPE a substantial test of 40 Hz sensory stimulation. The mixed result also illustrates why the overall primary endpoint, prespecified subgroups, multiplicity and safety all matter when interpreting a headline.
The results were presented at a conference and released by the sponsor. A peer-reviewed full trial report was not identified in the sources checked November 21. Until fuller data are available, the mild-subgroup findings should be treated as promising but unconfirmed. Spectris AD remains investigational and is not authorized by the U.S. Food and Drug Administration. The company says it plans to discuss a De Novo submission with FDA.
Disclosure Cognito Therapeutics sponsored HOPE and announced the results. MIT identifies Cognito as an MIT spin-off and Li-Huei Tsai and Ed Boyden as company co-founders. This article is not a treatment recommendation. Prepared with AI assistance; the current registry, sponsor materials and MIT account were checked November 21, 2026. The image is an AI-generated conceptual illustration with fictional people and abstract light-and-sound forms. It does not depict the actual device, trial participants, measured data or a clinical outcome.
